BR0115208A - Tratamento aperfeiçoado - Google Patents

Tratamento aperfeiçoado

Info

Publication number
BR0115208A
BR0115208A BR0115208-4A BR0115208A BR0115208A BR 0115208 A BR0115208 A BR 0115208A BR 0115208 A BR0115208 A BR 0115208A BR 0115208 A BR0115208 A BR 0115208A
Authority
BR
Brazil
Prior art keywords
iop
agents
enhanced treatment
susceptible
therapy
Prior art date
Application number
BR0115208-4A
Other languages
English (en)
Inventor
Richardson
Helene
Thom J Zimmerman
Challoner Teresa
Jonsson Per
Gr Nbladh Anna
Ihagen Potrik
Gieseker Donald
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22937766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0115208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of BR0115208A publication Critical patent/BR0115208A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

"TRATAMENTO APERFEIçOADO". A presente invenção está direcionada à utilização de dois ou mais agentes em combinação com capacidade de redução da pressão intra-ocular (IOP) em uma terapia com uma eficácia aperfeiçoada para tratar glaucoma avançado em tais pacientes que sofrem a partir de prejuízos relacionados à visão detectáveis, quando referidos agentes são administrados simultaneamente. A utilização combinada irá também encontrar vantagem em tratamento de indivíduos em necessidade de uma alta redução de IOP, tais como aqueles sendo expostos aos fatores de risco provocando neles susceptibilidade para prejuízos visuais.
BR0115208-4A 2000-11-13 2001-11-12 Tratamento aperfeiçoado BR0115208A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24812300P 2000-11-13 2000-11-13
PCT/SE2001/002499 WO2002038158A1 (en) 2000-11-13 2001-11-12 Improved treatment

Publications (1)

Publication Number Publication Date
BR0115208A true BR0115208A (pt) 2003-10-07

Family

ID=22937766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115208-4A BR0115208A (pt) 2000-11-13 2001-11-12 Tratamento aperfeiçoado

Country Status (17)

Country Link
US (1) US20030018079A1 (pt)
EP (1) EP1333837A1 (pt)
JP (1) JP2004513148A (pt)
KR (1) KR20030068150A (pt)
CN (1) CN1233324C (pt)
AR (1) AR035541A1 (pt)
AU (1) AU2002215277A1 (pt)
BR (1) BR0115208A (pt)
CA (1) CA2426049A1 (pt)
EA (1) EA200300560A1 (pt)
HU (1) HUP0400548A3 (pt)
MX (1) MXPA03004183A (pt)
NO (1) NO20032122L (pt)
NZ (1) NZ525817A (pt)
PL (1) PL362855A1 (pt)
WO (1) WO2002038158A1 (pt)
ZA (1) ZA200303771B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
AU2003253986A1 (en) * 2002-03-13 2003-09-29 Genomic Health Gene expression profiling in biopsied tumor tissues
ATE422894T1 (de) * 2002-03-21 2009-03-15 Cayman Chem Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
TWI350170B (en) 2002-08-29 2011-10-11 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US20070093507A1 (en) * 2003-09-05 2007-04-26 Lambrou George N Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
EP3643702A1 (en) 2004-01-05 2020-04-29 Nicox S.A. Prostaglandin derivatives
DE602004018990D1 (de) 2004-05-26 2009-02-26 Bayardo Arturo Jimenez Verfahren zur herstellung einer latanoprost-augenlösung und so hergestellte lösung
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US8629161B2 (en) 2005-06-21 2014-01-14 Kowa Co., Ltd. Preventive or remedy for glaucoma
ES2416334T3 (es) 2005-07-12 2013-07-31 Kowa Company. Ltd. Agente para la prevención o el tratamiento del glaucoma
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2010119305A1 (en) * 2009-04-14 2010-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of quaternary ammonium compounds in dissolving of latanoprost
CN102085175B (zh) * 2009-12-02 2013-01-30 沈阳兴齐眼药股份有限公司 一种眼用凝胶剂及其制备方法
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR20140010028A (ko) 2011-02-04 2014-01-23 코와 가부시키가이샤 녹내장 예방 또는 치료를 위한 약물 요법
CN102389433A (zh) * 2011-11-04 2012-03-28 兆科药业(香港)有限公司 一种药物组合物及其复方制剂
EP3730138B1 (en) 2017-12-21 2024-02-14 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination

Also Published As

Publication number Publication date
AR035541A1 (es) 2004-06-16
AU2002215277A1 (en) 2002-05-21
US20030018079A1 (en) 2003-01-23
ZA200303771B (en) 2004-05-17
NO20032122L (no) 2003-07-01
KR20030068150A (ko) 2003-08-19
CA2426049A1 (en) 2002-05-16
JP2004513148A (ja) 2004-04-30
NO20032122D0 (no) 2003-05-12
CN1473046A (zh) 2004-02-04
CN1233324C (zh) 2005-12-28
PL362855A1 (en) 2004-11-02
WO2002038158A8 (en) 2003-01-30
MXPA03004183A (es) 2004-12-02
HUP0400548A3 (en) 2007-05-29
EP1333837A1 (en) 2003-08-13
HUP0400548A2 (hu) 2004-06-28
WO2002038158A1 (en) 2002-05-16
NZ525817A (en) 2005-03-24
EA200300560A1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
BR0115208A (pt) Tratamento aperfeiçoado
BR0213975A (pt) Métodos para tratar doenças neovasculares oculares
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
WO2004004757A8 (en) Treatment for eye disorder
BRPI0415249A (pt) terapia de combinação para infecção por hcv
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BR0210013A (pt) Gel oftálmico de pirenzepina
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
BR0016918A (pt) Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas
BR0109753A (pt) Combinação farmacêutica, formulação farmacêutica, conjunto de partes, método para tratamento profilático ou terapêutico de um paciente que sofre de, ou é suscetìvel a, aterosclerose, e, usos de uma formulação, de uma combinação, ou de um conjunto de partes
BG101803A (en) Use of melatonin for treating patients suffering from drug addiction
EP1037622A4 (en) TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS
AU1601499A (en) Citicoline to treat motor neuron diseases and demyelinating diseases
Diao et al. [Retracted] Clinical Observation of Alternative Wave Electroacupuncture Combined with Lee’s Naprapathy in Treating Knee Osteoarthritis (Blood Stasis due to Qi Stagnation)
KR20010089975A (ko) 캡사이신을 이용한 만성 전립선염, 전립선 비대증, 치질및 발기부전 치료제
Gordon The nature of fibrositis and the influence of psychological states upon it
UA40487A (uk) Спосіб хірургічного лікування хворих з сторонніми тілами, локалізованими в "пограничній зоні" ока, та відшаруванням сітківки
Zhou Observation of the effects of the brain-located mild hypothermia therapy on cerebral hemorrhage
Goodman ALMANAC Breast Cancer Trial: Shoulder Function Favors Sentinel Node Biopsy
Makashova INFLUENCE OF MEDICAL THERAPY ON VISUAL FUNCTIONS HYDRODYNAMICS AND BLOOD-FLOW IN THE OPTIC NERVE IN PATIENTS WITH GLAUCOMA IN COMBINATION WITH MYOPIA
RU2002109353A (ru) Способ лимфотропной терапии больных открытоугольной глаукомой с нормализованным внутриглазным давлением
YOSHIKAWA et al. Effect on Intensive Pleoptics of Eccentric Fixation
James Major study shows AZT monotherapy inferior

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2021 DE 29/09/2009.